Articles

Regulatory

Published on 25 March 2020

Regulatory pathway for approval of ‘biosimilars’ in Iran

Abstract: Iran was the first country in the MENA (Middle East and North Africa) region to publish a legal framework for the registration of biosimilars. This framework is defined by...

Author(s): Jalal Naeli, MD

biopharmaceuticals, Iran, reference medicinal product

2.616 views

Read more →

Thank you to reviewers

Published on 09 March 2021

Thank you to reviewers 2020

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.611 views

Read more →

Abstracted Scientific Content

Published on 21 May 2021

Repurposing non-oncology drugs for cancer treatment

Submitted: 15 March 2021; Revised: 17 March 2021; Accepted: 18 March 2021; Published online first: 24 March 2021 Cancer is one of the leading causes of mortality in the world...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2021.1002.011

2.606 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2012

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.574 views

Read more →

Published on 27 September 2017

2017/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2017, Issue 3 Commentary Patent expiry and costs for anti­cancer medicines for clinical use Original Research A survey of Australian prescribers’ views...

2.563 views

Read more →

Published on 28 January 2019

2018/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s seventh volume Editorial Nomenclature for biosimilars; a continuing thorny issue Original Research Ongoing activities to influence the prescribing of proton...

2.547 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2013

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.539 views

Read more →

Published on 31 October 2016

2016/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2016, Issue 3 Letters to the Editor Is the EU ready for non-biological complex drug products? Commentary Biosimilars: achieving long-term savings and...

2.533 views

Read more →

Published on 21 June 2017

2017/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2017, Issue 2 Editorial Trends and challenges in biosimilars pricing and reimbursement policies in Europe and beyond Commentary Strategies...

2.503 views

Read more →

Published on 27 November 2019

2019/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2019, Issue 3 Commentary Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective Original Research Pharmacy chain drives...

2.496 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2014

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.484 views

Read more →

Perspective

Published on 19 April 2024

Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort

Abstract: In principle, biosimilars could mitigate the problem of the rising cost of biological medicines. However, the current stringent and non-harmonized regulatory practices hinder competition and contribute to the high...

Author(s): Adjunct Professor Pekka Kurki, MD, PhD

biosimilars, competition, controlled efficacy studies, harmonization

DOI: 10.5639/gabij.2024.1301.004

2.482 views

Read more →